Archive for March 2018

Immunoprecies Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins To 54%

March 28, 2018 – Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter ended January 31, 2018.  The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com. During the three months ended … Continue reading

Immunoprecise enters into Definitive Agreement to Acquire ModiQuest Research BV

Victoria, British Columbia, Canada, March 16, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “Immunoprecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has entered into the definitive share purchase agreement (the “Definitive Agreement”) to acquire all of the issued and outstanding shares of ModiQuest Research B.V. (“ModiQuest“) and Immulease B.V. (“Immulease”). … Continue reading